Bridgewater Associates’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-39,983
| Closed | -$5.6M | – | 1063 |
|
|
2025
Q3 | $5.6M | Buy |
+39,983
| New | +$5.4M | 0.02% | 472 |
|
|
2025
Q1 | – | Sell |
-70,033
| Closed | -$10.7M | – | 688 |
|
|
2024
Q4 | $10.7M | Sell |
70,033
-2,071
| -3% | -$349K | 0.05% | 247 |
|
|
2024
Q3 | $14M | Buy |
72,104
+55,688
| +339% | +$11.7M | 0.08% | 210 |
|
|
2024
Q2 | $3.81M | Sell |
16,416
-28,536
| -63% | -$6.2M | 0.02% | 407 |
|
|
2024
Q1 | $9.69M | Sell |
44,952
-98,334
| -69% | -$23M | 0.05% | 259 |
|
|
2023
Q4 | $37.1M | Sell |
143,286
-7,591
| -5% | -$1.86M | 0.21% | 86 |
|
|
2023
Q3 | $38.8M | Buy |
150,877
+24,458
| +19% | +$6.54M | 0.23% | 84 |
|
|
2023
Q2 | $36M | Sell |
126,419
-21,306
| -14% | -$6.34M | 0.22% | 87 |
|
|
2023
Q1 | $41.1M | Buy |
147,725
+36,928
| +33% | +$10.2M | 0.25% | 81 |
|
|
2022
Q4 | $30.7M | Sell |
110,797
-2,826
| -2% | -$798K | 0.17% | 115 |
|
|
2022
Q3 | $30.3M | Sell |
113,623
-154,308
| -58% | -$32.8M | 0.15% | 118 |
|
|
2022
Q2 | $54.6M | Buy |
267,931
+230,412
| +614% | +$47.1M | 0.23% | 91 |
|
|
2022
Q1 | $7.9M | Buy |
37,519
+25,115
| +202% | +$5.46M | 0.03% | 350 |
|
|
2021
Q4 | $2.98M | Sell |
12,404
-218
| -2% | -$56.1K | 0.02% | 404 |
|
|
2021
Q3 | $3.57M | Sell |
12,622
-5,234
| -29% | -$1.72M | 0.02% | 343 |
|
|
2021
Q2 | $6.18M | Buy |
17,856
+9,459
| +113% | +$2.87M | 0.04% | 293 |
|
|
2021
Q1 | $2.35M | Buy |
+8,397
| New | +$2.26M | 0.02% | 268 |
|
|
2019
Q4 | – | Sell |
-237,455
| Closed | -$55.3M | – | 481 |
|
|
2019
Q3 | $55.3M | Sell |
237,455
-11,478
| -5% | -$2.67M | 0.49% | 20 |
|
|
2019
Q2 | $58.2M | Buy |
248,933
+8,555
| +4% | +$1.98M | 0.46% | 20 |
|
|
2019
Q1 | $56.8M | Buy |
240,378
+194,483
| +424% | +$61.2M | 0.35% | 18 |
|
|
2018
Q4 | $13.8M | Buy |
45,895
+25,463
| +125% | +$8.13M | 0.13% | 91 |
|
|
2018
Q3 | $7.22M | Sell |
20,432
-2,387
| -10% | -$822K | 0.07% | 96 |
|
|
2018
Q2 | $6.62M | Sell |
22,819
-54,378
| -70% | -$15.3M | 0.07% | 113 |
|
|
2018
Q1 | $21.1M | Buy |
+77,197
| New | +$24M | 0.2% | 34 |
|
|
2017
Q4 | – | Sell |
-44,198
| Closed | -$13.8M | – | 255 |
|
|
2017
Q3 | $13.8M | Sell |
44,198
-783
| -2% | -$232K | 0.09% | 45 |
|
|
2017
Q2 | $12.2M | Sell |
44,981
-466
| -1% | -$123K | 0.11% | 44 |
|
|
2017
Q1 | $12.4M | Buy |
+45,447
| New | +$12.9M | 0.14% | 41 |
|
|
2016
Q4 | – | Sell |
-900
| Closed | -$282K | – | 282 |
|
|
2016
Q3 | $282K | Sell |
900
-50,561
| -98% | -$15M | ﹤0.01% | 272 |
|
|
2016
Q2 | $12.4M | Buy |
51,461
+28,355
| +123% | +$7.47M | 0.16% | 51 |
|
|
2016
Q1 | $6.01M | Sell |
23,106
-2,000
| -8% | -$528K | 0.08% | 105 |
|
|
2015
Q4 | $7.69M | Buy |
25,106
+10,340
| +70% | +$2.97M | 0.1% | 90 |
|
|
2015
Q3 | $4.31M | Buy |
+14,766
| New | +$4.88M | 0.06% | 145 |
|
|
2015
Q2 | – | Sell |
-20,446
| Closed | -$8.63M | – | 321 |
|
|
2015
Q1 | $8.63M | Buy |
20,446
+5,300
| +35% | +$2.09M | 0.07% | 71 |
|
|
2014
Q4 | $5.14M | Buy |
15,146
+13,500
| +820% | +$4.37M | 0.04% | 102 |
|
|
2014
Q3 | $545K | Buy |
+1,646
| New | +$543K | ﹤0.01% | 270 |
|
|
2014
Q1 | – | Sell |
-19,057
| Closed | -$5.33M | – | 348 |
|
|
2013
Q4 | $5.33M | Buy |
19,057
+12,883
| +209% | +$3.33M | 0.04% | 104 |
|
|
2013
Q3 | $1.49M | Sell |
6,174
-4,338
| -41% | -$971K | 0.01% | 182 |
|
|
2013
Q2 | $2.26M | Buy |
+10,512
| New | +$2.25M | 0.02% | 147 |
|
Other funds holding BIIB
Bridgewater Associates's BIIB Position: Q4 2025 in Review
Bridgewater Associates sold out of Biogen (BIIB) in Q4 2025, closing a stake of 39,983 shares — an estimated $5.6M sold.
Bridgewater Associates first reported a position in BIIB in Q2 2013 and held it in 38 quarters. The position peaked at $58.2M in Q2 2019. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Bridgewater Associates reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
- Bridgewater Associates sold 39,983 Biogen shares in Q4 2025, an estimated $5.6M.
- Bridgewater Associates first reported a position in Biogen in Q2 2013 and held it in 38 quarters.
- Bridgewater Associates's Biogen position peaked at $58.2M in Q2 2019.
- 997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Bridgewater Associates's 13F filing for Q4 2025, filed 13 Feb 2026.